Chronic pain deserves more than pills.
The pain didn't appear overnight. The solution shouldn't either.
Chronic musculoskeletal pain — osteoarthritis, shoulder impingement, tendinopathy — is driven by persistent inflammation and structural tissue changes. A single treatment can't reverse that. What works is an accretive approach: each session builds on the prior session's biological effects, compounding over a 6–8 week course into lasting structural and functional change.
Sustained pain decrease for OA
Not just immediate relief — sustained improvement over the treatment course.
Why one-time treatments fail — and why accretive biology works
Acute pain is a signal. Chronic pain is a system — an entrenched loop of inflammation, structural tissue changes, sensitized nerve pathways, and limited local circulation that sustains and amplifies the pain signal long after the original injury.
Pain medication addresses the signal. It does not address the system. That is why chronic pain patients experience temporary relief but no durable improvement — and why opioid dependence becomes a risk, not a solution.
The accretive model works differently. Each treatment session adds to the prior session's effects: inflammation decreases progressively, new capillaries form and mature, tissue remodeling begins and compounds. The result is not temporary relief but structural change — the kind that shows up as sustained functional improvement at 6–8 weeks.
Opioids
Treat the signal. No structural change. High dependency risk.
NSAIDs
Reduce inflammation acutely. GI and cardiovascular risks at long-term use.
Accretive tPEMF
Each session builds. Inflammation decreases progressively. Structural change at 6–8 weeks.
No addiction risk
No pharmaceutical compounds. Zero dependency or withdrawal profile.
Where tPEMF research focuses
Published studies on pulsed electromagnetic field therapy span multiple chronic musculoskeletal conditions. The mechanism — anti-inflammatory cascade, neovascularization, collagen synthesis — is condition-general.
Knee & Hip Osteoarthritis
OA is not simply wear-and-tear — it is a chronic inflammatory condition. The cartilage loss is driven by inflammatory cytokines and poor perfusion of the joint space. Studies show 44% immediate pain reduction and 60% sustained improvement over time.
60% sustained pain decrease
Source: SofPulse clinical data
Subacromial Shoulder Impingement
Impingement syndrome involves chronic inflammation of the bursa and rotator cuff tendons. Peer-reviewed trials show significantly greater improvements in pain scores, range of motion, and functional outcome versus sham treatment at both 1 and 3 months.
Greater pain, ROM, and function vs. sham at 1 and 3 months
Source: Peer-reviewed controlled trial
Tendinopathy
Achilles, patellar, and rotator cuff tendinopathies involve failed tissue healing — the tendon generates reactive tissue rather than properly regenerating collagen. PEMF has been shown to accelerate tendon healing by 69% compared to control.
69% acceleration in tendon healing
Source: Strauch & Pilla, 2006
Ankle Sprains (Grade I / II)
Acute ankle sprains cause immediate edema that, if not resolved, delays return to activity and predisposes to chronic instability. Studies show a 700% reduction in edema for Grade I and II sprains — dramatically faster recovery and reduced swelling-driven pain.
700% reduction in edema
Source: SofPulse clinical data
Key data points from peer-reviewed research
The 2024 systematic review in the MDPI Journal of Clinical Medicine analyzed 17 studies and 1,197 patients — finding consistent improvements in pain, stiffness, and function across OA populations.
Immediate pain decrease in early knee OA
Source: SofPulse clinical data
Key findingSustained pain decrease over treatment course — OA
Source: SofPulse clinical data
Reduction in edema — Grade I/II ankle sprains
Source: SofPulse clinical data
Peer-reviewed PEMF studies published (1981–2023)
Source: Published literature index
Studies in systematic review — pain, stiffness, function improvements
Source: MDPI Journal of Clinical Medicine, 2024
Patients included in 2024 systematic review
Source: MDPI Journal of Clinical Medicine, 2024
Statistics cited from SofPulse clinical data, Strauch & Pilla (2006), and the 2024 MDPI Journal of Clinical Medicine systematic review. All data are drawn from published peer-reviewed research. This summary is educational and does not constitute a therapeutic claim.
What happens across a 6–8 week course
The biological changes are cumulative. Each phase builds on the prior one. This is why the sustained improvement data — measured at 6–8 weeks — looks different from the immediate post-session data.
Inflammation modulation begins
The electromagnetic field modulates NF-κB signaling — the master regulator of inflammatory gene expression. Pro-inflammatory cytokines (IL-1β, TNF-α) begin to decrease. Patients often report subtle changes in morning stiffness and swelling.
Structural changes become measurable
Nitric oxide release improves microvascular perfusion of the affected joint or tendon. Fibroblast activation begins collagen remodeling. Objective improvements in range of motion and functional scores become measurable in clinical assessment.
Sustained functional improvement
The tissue-level changes from prior weeks translate into sustained functional gains — the 60% sustained pain decrease seen in OA studies is measured at this phase. Patients experience improved activity tolerance, not just momentary relief.
Why 15-minute sessions work
Each session takes approximately 15 minutes. The biological response — triggered by targeted electromagnetic stimulation — continues for hours after the session ends. The cumulative effect of daily or twice-daily sessions over 6–8 weeks produces the sustained improvements seen in peer-reviewed OA studies.
Real Cost of Chronic Pain
What temporary relief costs over time — vs. one lasting course
Most OA and MSK patients cycle through NSAIDs, cortisone, and PT for years. Each provides temporary relief. None addresses the underlying biology. The costs compound.
How long have you been managing this pain?
Used to estimate accumulated cost of current treatments
Current treatments
Select all that apply — costs are estimated US out-of-pocket averages
Your federal tax bracket
Determines your HSA/FSA savings on the tPEMF device
Current approach — 2 years($1,080/yr)
tPEMF 8-week course (device)
FDA cleared · HSA/FSA eligible · one course, lasting biology
You spend this much more on temp relief
Over 2 years vs. one tPEMF course
Cost estimates are approximate US out-of-pocket averages: OTC NSAIDs ~$40/mo; prescription pain medication ~$60/mo after insurance copays; cortisone injections ~$300 each, 2 per year; physical therapy ~$60/session after insurance, 20 sessions/year. Your actual costs may differ. tPEMF net cost reflects HSA/FSA pre-tax savings at the selected bracket. A physician prescription is required to use HSA/FSA funds.
Talk to your physician about tPEMF for chronic pain
The research summarized here represents published, peer-reviewed evidence on pulsed electromagnetic field therapy. Bring these data points to your next appointment and ask whether tPEMF is appropriate for your condition.
No opioid risk. No pharmaceutical interactions. 15-minute sessions. HSA/FSA eligible with physician prescription.
Regulatory Note
The electroceutical technology described on this page is CE Marked (Class 2a) for pain, wounds, and edema in the European Union. In the United States, this technology is FDA cleared for post-operative pain and edema management. Ask your physician about whether tPEMF is appropriate for your specific condition and clinical context.
This page is educational content about published research on pulsed electromagnetic field (PEMF) therapy. It does not constitute a therapeutic claim, medical advice, or promotion of off-label use. Individual outcomes vary. Consult a licensed physician before beginning any treatment course. SofPulse is a registered trademark of SofPulse Inc. This site is not affiliated with or endorsed by SofPulse Inc.
Powered by SofPulse tPEMF technology.